^
    Back
    Association details:
    Biomarker:BIRC3 deletion
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Exome Sequencing of Relapsed Multiple Myeloma Combined with Pooled CRISPR/Cas9 Screens Identifies Gene Mutations Associated with Drug-Specific Resistance

    Published date:
    11/06/2019
    Excerpt:
    For bortezomib, inactivation of only one gene, TMC2, encoding a transmembrane protein was associated with resistance in two cell lines whereas BIRC3 inactivation provided increased susceptibility to bortezomib.
    DOI:
    https://doi.org/10.1182/blood-2019-131245